Thursday, February 22, 2018, 12:00 p.m. to 1:00 p.m. PT.
This educational webinar is for clinicians across the continuum of care to raise awareness of the threat of antibiotic resistance and the importance of appropriate prescribing and use; and to differentiate and evaluate approaches to antibiotic stewardship.
Click here to view the webinar recording and presentation
After attending this webinar, the attendee will be able to:
• Understand the current landscape of antibiotic resistance.
• Be familiar with tactical, strategic, and grand strategic approaches to antibiotic stewardship.
• Be familiar with strengths and weakness of stewardship approaches.
Speaker: Brad Spellberg, MD, FIDSA, FACP
Brad Spellberg, MD, is the Chief Medical Officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center. He is also a Professor of Clinical Medicine and Associate Dean for Clinical Affairs at the Keck School of Medicine at USC. He received his BA in Molecular Cell Biology-Immunology from UC Berkeley. He then attended medical school at UCLA, where he received numerous academic honors, including serving as the UCLA AOA Chapter Co-President, and winning the prestigious Stafford Warren award for the topic academic performance in his graduating class. Dr. Spellberg completed his Residency in Internal Medicine and subspecialty fellowship in Infectious Diseases at Harbor-UCLA Medical Center.
Dr. Spellberg has extensive administrative, patient care, and teaching activities. He has worked for the last 3 years to transform the quality and efficiency of care delivered at LAC+USC Medical Center, the largest public hospital in the US west of the Mississippi. In this role he has 18 non-clinical direct reports, and another 18 Chiefs of Clinical Services reporting to him. He is responsible for oversight of the $140 million dollar Medical School Affiliation Agreement with USC, and 1500 physicians, including 750 full time physicians. He has altered all aspects of hospital operations, from HR, to patient flow, to personnel, to UR, Social Services, medical documentation and billing, clinical care, and etc.
Dr. Spellberg may be the only Chief Medical Officer in the U.S. who not only continues to be actively clinically, staffing both Internal Medicine ward teams and Infectious Diseases consulting service, but also maintains an active NIH-funded basic science laboratory. His NIH-funded research interests are diverse, ranging from basic immunology and vaccinology, to pure clinical and outcomes research, to process improvement work related to delivery of care, focusing on safety net hospitals. His laboratory research has focused on developing a vaccine that targets the bacterium Staphylococcus aureus and the fungus Candida; the vaccine is undergoing clinical development. Dr. Spellberg is currently working on the immunology, vaccinology, and host defense against highly resistant Gram negative bacilli, including Acinetobacter and carbapenem-resistant Enterobacteriaceae infections. Dr. Spellberg has also co-founded 3 biotechnology start up companies, which have resulted in 3 molecules that are in active clinical development (phase I-III clinical trials).
Finally, at the national level, Dr. Spellberg has worked extensively with the Infectious Diseases Society of America (IDSA) to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. His research regarding new drug development was a cornerstone of the IDSA’s white paper, Bad Bugs, No Drugs, and has been cited extensively in medical literature and on Capitol Hill. As a member and then co-chair of the IDSA’s Antimicrobial Availability Task Force (AATF), he first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Finally, Dr. Spellberg is the author of Rising Plague, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development.